Amneal Pharmaceuticals Inc (AMRX) 13F Ownership Report (Q2 2026)

Amneal Pharmaceuticals disclosed in an Aug. 10, 2026 8-K that it entered into two agreements tied to an acquisition. It signed an amendment to its stockholders agreement with Vikram Patel, clarifying that stock issued in the deal counts toward the Amneal Group's ownership. It also closed Amendment No. 4 to its term loan credit agreement, adding a $350 million incremental term loan from Bank of America, with JPMorgan Chase as administrative agent, to help fund the acquisition. The filing excerpt doesn't describe the acquisition itself, so key deal terms remain undisclosed.

AI summary pending

Amneal Pharmaceuticals (AMRX) held a special stockholder meeting on July 31, 2026, and shareholders approved two proposals tied to its planned acquisition of Kashiv BioSciences: the purchase agreement itself and the issuance of 28,942,108 common shares to the sellers. Proposal 1 passed with roughly 138.3 million votes in favor from disinterested stockholders, and Proposal 2 passed with about 286.7 million votes in favor, so no adjournment was needed. The company says the deal is expected to close in the second half of 2026 if remaining conditions are met.

Amneal Pharmaceuticals, Inc. (AMRX) issued its second-quarter 2026 earnings release on July 30, 2026, covering the three months ended June 30, 2026. This 8-K is the standard notice that the press release was issued and attached as Exhibit 99.1; the actual earnings figures aren't included in this excerpt. The filing also flags a separate Regulation FD disclosure under Item 7.01, but its contents aren't detailed here.